FDA Rejects Tricida Chronic Kidney Disease Drug, More Data Needed

Tricada’s bid for speedy approval of drug for a condition caused by chronic kidney disease has been rejected by the FDA, which is asking for data that may require conducting another clinical trial. The South San Francisco-based biotech had tested its drug, veverimer, in a Phase 3 study and a follow-on extension study, both of […]

Click to view original post